1Timmerman R, Galvin J, Michalski J, et al. Accreditation andquality assurance for Radiation Therapy Oncology Group : Multi-center clinical trials using Stereotactic Body Radiation Therapy inlung cancer[ J]. Acta Oncol. 2006; 45(7) :779 ~ 86.
2Andratschke N , Zimmermann F,Boehm E, et al. Stereotactic ra-diotherapy of histologically proven inoperable stage I non - smallcell lung cancer: Patterns of failure[ J]. Radiother Oncol, 2011,101(2) :245 -9.
3Onishi H, Shirato H, Nagata Y, et al. Hypofractionated stereotacticradiotherapy ( HypoFXSRT) for stage I non-small cell lung cancer;updated results of 257 patients in a Japanese multi -institutionalstudy[ J]. J Thorac Oncol, 2007 ,2(1 Suppl 3) ;S94 - 100.
4Takeda A, Sanuki N, Kunieda E, et al. Stereotactic body radio-therapy for primary lung cancer at a dose of 50 Gy total in five frac-tions to the periphery of the planning target volume calculated usinga superposition algorithm[ J]. Int J Radiat Oncol Biol Phys, 2009,73(2) :442 -8.
5Timmerman R,Paulus R, Galvin J, et al. Stereotactic body radia-tion therapy for inoperable early stage lung cancer [ J]. JAMA,2010,17; 303(11) :1070 -6.
6Louie AY, Rodrigues G, Hannouf M, et al. Stereotactic body ra-diotherapy versus surgery for medically operable stage I non-small-cell lung cancer: a markov model-based decision analysis[ J] . IntJ Radiat Oncol Biol Phys, 2011,15 ;81 (4) :964 -73.
7Crabtree TD,Denlinger CE, Meyers BF, et al. Stereotactic bodyradiation therapy versus surgical resection for stage I non-small celllung cancer[J]. J Thorac Cardiovasc Surg, 2010,140(2) :377 -86.
8Kates M, Perez X, Gribetz J, et al. Validation of a model to predictperioperative mortality from lung cancer resection in the elderly[J]. Am J Respir Crit Care Med, 2009,179(5) :390-5.
9Chen F, Matsuo Y, Yoshizawa A, et al. Salvage lung resection fornon-small cell lung cancer after stereotactic body radiotherapy ininitially operable patients[ J]. J Thorac Oncol,2010 ,5( 12) : 1999-2002.
10Curran WJ Jr, Paulus R, Langer CJ,et al. Sequential vs. concur-rent chemoradiation for stage III non-small cell lung cancer: ran-domized phase ID trial RTOG 9410f J]. J Natl Cancer Inst, 2011 ,103(19) .-1452 -60.
